TORONTO--(BUSINESS WIRE)-- Cybin Inc. (CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative ...

Inhibikase Therapeutics ( (IKT)) has shared an announcement. On December 19, 2025, Inhibikase Therapeutics, Inc. filed a prospectus supplement with the U.S. Securities and Exchange Commission to ...

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental ...

After market close on Tuesday, FuelCell said in a filing it entered into an amended sales agreement to increase the amount of shares that may be sold under its sales agreement to $200 million.

EPR Properties is upgraded from 'sell' to 'buy' after a 16% price drop and rapid portfolio de-risking. EPR's aggressive theater divestitures and reinvestment in experiential assets have driven 6.1% ...